Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model
暂无分享,去创建一个
[1] J. Goldie,et al. A model for the resistance of tumor cells to cancer chemotherapeutic agents , 1983 .
[2] F L Pereira,et al. A new optimization based approach to experimental combination chemotherapy. , 1995, Frontiers of medical and biological engineering : the international journal of the Japan Society of Medical Electronics and Biological Engineering.
[3] J. M. Murray,et al. Some optimal control problems in cancer chemotherapy with a toxicity limit. , 1990, Mathematical biosciences.
[4] R. B. Martin,et al. Optimal control drug scheduling of cancer chemotherapy , 1992, Autom..
[5] T. Vincent,et al. Optimal control analysis in the chemotherapy of IgG multiple myeloma. , 1977, Bulletin of mathematical biology.
[6] Petre Stoica,et al. Decentralized Control , 2018, The Control Systems Handbook.
[7] M E Fisher,et al. A mathematical model of cancer chemotherapy with an optimal selection of parameters. , 1990, Mathematical biosciences.
[8] C. Nicolini,et al. Mathematical approaches to optimization of cancer chemotherapy. , 1979, Bulletin of mathematical biology.
[9] A Iliadis,et al. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study. , 1996, European journal of cancer.
[10] B. Chabner,et al. Potential roles for preclinical pharmacology in phase I clinical trials. , 1986, Cancer treatment reports.
[11] J. M. Murray,et al. Optimal drug regimens in cancer chemotherapy for single drugs that block progression through the cell cycle. , 1994, Mathematical biosciences.
[12] L. Sheiner,et al. Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.
[13] Mark J. Ratain,et al. Principles of Antineoplastic Drug Development and Pharmacology , 1996 .
[14] A Iliadis,et al. Dynamical dosage regimen calculations in linear pharmacokinetics. , 1988, Computers and biomedical research, an international journal.
[15] V. Oliverio,et al. Clinical pharmacology of anticancer drugs. , 1977, Seminars in oncology.
[16] Richard Bellman,et al. Differential-Difference Equations , 1967 .
[17] L B Sheiner,et al. Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.
[18] Lawrence M. Fagan,et al. Combining Physiologic Models and Symbolic Methods to Interpret Time-Varying Patient Data* , 1991, Methods of Information in Medicine.
[19] A Swierniak,et al. Optimal control problems arising in cell‐cycle‐specific cancer chemotherapy , 1996, Cell proliferation.
[20] M A Woodbury,et al. A new model for tumor growth analysis based on a postulated inhibitory substance. , 1980, Computers and biomedical research, an international journal.
[21] A. Papoulis. Signal Analysis , 1977 .
[22] John G. Wagner,et al. Fundamentals of Clinical Pharmacokinetics , 1975 .
[23] George W. Swan,et al. Applications of Optimal Control Theory in Biomedicine , 1984 .
[24] G. W. Swan. Role of optimal control theory in cancer chemotherapy. , 1990, Mathematical biosciences.
[25] Malur K. Sundareshan,et al. Periodic optimization of a class of bilinear systems with application to control of cell proliferation and cancer therapy , 1985, IEEE Transactions on Systems, Man, and Cybernetics.
[26] Nicholas H. G. Holford,et al. The Population Approach: Rationale, Methods, and Applications in Clinical Pharmacology and Drug Development , 1994 .
[27] D. F. Rufer. Implementation and Properties of a Method for the Identification of Nonlinear Continuous Time Models , 1978 .
[28] J. M. Murray,et al. Optimal control for a cancer chemotherapy problem with general growth and loss functions. , 1990, Mathematical biosciences.